


## Product Details

Product name:	Anti-HER2/neu & HER3 (Zenocutuzumab Biosimilar)	SKU:	BIO1004SM
Target Name:	HER2/neu & HER3	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P04626 & P21860	Concentration:	Lyophilized
Clone#:	Zenocutuzumab (Bispecific)	Isotype:	IgG-like
Reactivity:	Human	Calculated M.W.:	145.88 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH <sub>2</sub> O	Purification:	Protein A


## Data

### Purity: SDS-PAGE




Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) on SDS-PAGE under reducing (R) condition. The purity of the proteins greater than 95%.

### Purity: SEC-HPLC




The purity of Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) is 100.00%, determined by SEC-HPLC.

### ELISA



Zenocutuzumab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Zenocutuzumab bound to hu-HER2-his, and the EC50 was 0.017 nM.


### Bioactivity: FACS



Zenocutuzumab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE), and tested by flow cytometry. As shown in fig, Zenocutuzumab bound to BT474 cells, and the EC50 was 1.277 nM.


**Important Note:** This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

### Bioactivity: FACS



Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, FcPE) , and test by flow cytometry. As shown in fig, Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and the EC50 was 0.879 nM.

### Function: ADCC



Co-incubation of Zenocutuzumab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zenocutuzumab. As shown in fig, Zenocutuzumab has ADCC activity and the IC50 was 0.031 nM.